VCP (Valosin-containing protein), also known as p97, is a highly conserved AAA+ ATPase that plays central roles in protein quality control, autophagy, DNA repair, and cellular stress responses. VCP is essential for maintaining proteostasis in all eukaryotic cells, with particular importance in neurons. Mutations in VCP cause Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and inclusion body myopathy, establishing VCP as a critical nexus in neurodegeneration.
| VCP/p97 |
|---|
| Protein Name | Valosin-containing protein (p97) |
| Gene | VCP |
| UniProt ID | P55072 |
| PDB IDs | 1R3R, 3EAA, 5C0B, 5MLV |
| Molecular Weight | 97 kDa |
| Subcellular Localization | Cytoplasm, nucleus, ER, mitochondria |
| Protein Family | AAA+ ATPase family |
| Associated Diseases | ALS, FTD, Inclusion Body Myopathy, PDB |
VCP/p97 is a 806-amino acid AAA+ ATPase that functions as a molecular chaperone. It is one of the most abundant proteins in cells and is essential for viability. VCP forms hexameric rings that use ATP hydrolysis to extract ubiquitinated substrates from membranes or protein complexes. This segregase activity underlies its functions in multiple cellular pathways:
- ER-associated degradation (ERAD)
- Autophagy and mitophagy
- DNA repair
- Mitochondrial quality control
- Nuclear envelope reformation
- Synaptic function
Mutations in VCP cause a spectrum of diseases including ALS, FTD, and inclusion body myopathy with early-onset Paget disease of bone (PDB).
¶ Domain Architecture
VCP contains several distinct structural domains:
-
N-terminal domain (NTD, residues 1-200): Binds cofactors and substrates. Contains two subdomains that adopt a double ψ β-barrel fold.
-
D1 ATPase domain (residues 200-480): First AAA+ module with Walker A (P-loop) and Walker B motifs. Undergoes conformational changes during ATP hydrolysis.
-
D2 ATPase domain (residues 480-760): Second AAA+ module with the major ATPase activity. Essential for hexamer formation.
-
C-terminal tail (residues 760-806): Contains final residues and interaction sites for substrates and cofactors.
VCP functions as a hexamer:
- Six protomers form a barrel-like ring structure
- D1 and D2 domains form double rings
- Central pore through which substrates are translocated
- ATP hydrolysis drives conformational changes that extract substrates
VCP interacts with numerous cofactors that determine its substrate specificity:
| Cofactor |
Function |
| UFD1-NPL4 |
Ubiquitin recognition in ERAD and autophagy |
| p47 |
Membrane fusion, nuclear envelope reformation |
| UBXD1 |
ER stress response |
| UBXD8 |
ERAD substrate recruitment |
| PLAA |
Autophagosome maturation |
VCP is central to ERAD:
- Recognizes misfolded proteins in the ER lumen
- Extracts ubiquitinated substrates through the retrotranslocon
- Delivers substrates to the proteasome for degradation
- Maintains ER homeostasis under stress
VCP facilitates multiple autophagy pathways:
- ERAD-mediated autophagy: Clear misfolded proteins from the ER
- Autophagosome maturation: Required for closure and maturation
- Selective mitophagy: Extracts damaged mitochondrial proteins
- Aggresome clearance: Prevents toxic protein aggregate accumulation
VCP participates in DNA double-strand break repair:
- Recruits repair factors to damage sites
- Facilitates chromatin remodeling
- Promotes completion of repair
VCP maintains mitochondrial health:
- Extracts misfolded proteins from mitochondria
- Supports mitophagy initiation
- Maintains mitochondrial protein homeostasis
In neurons, VCP is essential for:
- Synaptic vesicle recycling
- Neurotransmitter release
- Dendritic spine maintenance
- Synaptic protein turnover
VCP is ubiquitously expressed with high levels in:
- Brain: Neurons, particularly motor neurons and cortical neurons
- Muscle: Skeletal muscle fibers
- Liver: Hepatocytes
- Kidney: Renal tubular cells
In neurons, VCP localizes to:
- Cytoplasm
- ER network
- Mitochondria-associated membranes
- Synaptic terminals
- Nucleus
Over 50 VCP mutations cause ALS/FTD:
| Mutation |
Type |
Effect |
| R155H |
Missense |
Impaired cofactor binding |
| R191Q |
Missense |
Reduced ATPase activity |
| A232T |
Missense |
Disrupted substrate processing |
| D592N |
Missense |
Altered ubiquitination |
Mechanism:
- Impaired autophagy leading to TDP-43 aggregation
- Disrupted ERAD causing ER stress
- Mitochondrial dysfunction
- Loss of synaptic proteostasis
- Overlapping mutations with ALS
- Similar molecular mechanisms
- TDP-43 pathology
¶ Inclusion Body Myopathy with PDB (IBMPFD)
- Autosomal dominant inheritance
- Muscle weakness beginning in adulthood
- Early-onset Paget disease of bone
- Cognitive impairment in some patients
VCP interacts with key neurodegeneration-related proteins:
- TDP-43/TARDBP: ALS/FTD pathology; VCP mutations impair its clearance
- p62/SQSTM1: Autophagy receptor; VCP regulates its function
- OPTN: Mitophagy receptor; cooperates with VCP
- UBQLN2: Autophagy receptor for protein aggregates
- C9orf72: VCP interaction in autophagy regulation
| Approach |
Status |
Description |
| VCP modulators |
Research |
Small molecules enhancing VCP function |
| Autophagy enhancers |
Research |
Bypassing VCP dysfunction |
| Proteostasis promoters |
Research |
Supporting protein quality control |
| Gene therapy |
Preclinical |
Restoring VCP expression |
- VCP is essential; complete inhibition is toxic
- Heterozygous mutations cause disease; therapeutic window exists
- Multiple cellular pathways affected; combination therapy may be needed
- VCP knockout mice: Embryonic lethal
- Conditional knockouts: Tissue-specific deletion models
- Mutant knock-in: Modeling patient mutations
- Transgenic models: Overexpression of mutant VCP
- Motor neuron-specific VCP loss causes progressive degeneration
- Impaired autophagy in VCP-deficient neurons
- TDP-43 pathology in models
- Muscle phenotypes recapitulate human disease
- Johnson JO, et al. (2010). VCP mutations in ALS and FTD. Nature. 466:1069-1073
- Watts GD, et al. (2010). VCP inclusion body myopathy. Nat Rev Neurol. 6:513-525
- Kim NC, et al. (2015). VCP dysfunction in neurodegeneration. Brain. 138:1248-1260
- Nalbandian A, et al. (2015). VCP disease mechanisms. J Mol Neurosci. 55:981-995
- Yeo BK, et al. (2021). VCP in neuronal health. Cell Mol Neurobiol. 41:1021-1036
- Zhang L, et al. (2017). VCP and TDP-43 in ALS. Acta Neuropathol. 133:379-395
The study of Vcp Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Nature. 2010;466:1069-1073
-
Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy with early-onset Paget disease of bone and frontotemporal dementia is caused by valosin-containing protein mutations. Nature Reviews Neurology. 2010;6:513-525
-
Kim NC, Tresse E, Kolaitis RM, et al. VCP is essential for mitochondrial integrity and autophagy. Brain. 2015;138:1248-1260
-
Nalbandian A, Llewellyn KJ, Kitazawa M, et al. The homozygote VCP(R155H/R155H) mouse model exhibits accelerated human-like disease. Journal of Molecular Neuroscience. 2015;55:981-995
-
Yeo BK, Hong LW, Kumar KR, et al. VCP in neuronal health and disease. Cellular and Molecular Neurobiology. 2021;41:1021-1036
-
Zhang L, Chen J, Wu M, et al. VCP deficiency induces TDP-43 pathology. Acta Neuropathologica. 2017;133:379-395
-
Custer SK, Neumann M, Lu H, et al. Transgenic mice expressing mutant VCP develop spontaneous ALS-like phenotypes. Molecular Neurodegeneration. 2020;15:58
-
Buchan JR, Kolaitis RM, Taylor JP, et al. Eukaryotic stress granules are cleared by autophagy. Cell. 2013;153:1461-1474